Clinical Trial

REZŪM vs. Dual Drug Therapy for Symptomatic Benign Prostatic Hyperplasia in Sexually Active Men

Study acronym: VAPEUR
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The study objective is to compare water vapor thermotherapy with the REZŪM™ System to dual drug therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to alpha-blocker monotherapy in sexually active men.
Protocol Amendment History 1 change
minor Completion moved earlier: 2027-03 -> 2026-12 2026-08-13
Trial Details
NCT Number NCT04838769
Lead Sponsor Boston Scientific Corporation
Conditions Benign Prostatic Hyperplasia (BPH)
Enrollment 155 participants
Start Date 2021-09-15
Primary Completion 2025-12-11 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-12